Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 22, 2018 - The FDA announced the approval of Dompé's Oxervate (cenegermin-bkbj) for the treatment of neurotrophic keratitis.
Download PDF
Return to publications
